Business Context and Reporting Period
This Form 8-K filing by McKesson Corporation (MCKESSON CORP) was submitted on December 18, 2017. The report addresses a significant change in executive leadership regarding the Chief Financial Officer position.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure: James A. Beer is resigning as Executive Vice President and Chief Financial Officer, effective December 31, 2017, to become CFO of Atlassian Corporation PLC.
- Appointment: Britt Vitalone has been appointed as the new Executive Vice President and Chief Financial Officer, effective January 1, 2018.
- Background: Mr. Vitalone, age 48, currently serves as Senior Vice President and CFO of U.S. Pharmaceutical and McKesson Specialty Health. He has been with McKesson since 2006 and previously held roles in corporate financial planning, M&A finance, and the Medical-Surgical business.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or specific risk factors related to operations. Regarding compensation, the text states that compensation for Mr. Vitalone associated with his new position has not been determined at the time of filing. The press release accompanying this filing is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the exact effective date of Britt Vitalone's appointment (January 1, 2018) and James A. Beer's departure (December 31, 2017).
- Review the attached press release (Exhibit 99.1) for any additional details on the transition plan not included in the 8-K text.
- Monitor future filings for the finalized compensation package for the new CFO.
- Confirm the strategic implications of the CFO transition on upcoming earnings reports.